Aditxt Inc. (ADTX) said that it has launched high-sensitivity neutralizing antibody test to detect individual immune response to COVID-19.
In Monday pre-market trading, ADTX was trading at $2.68 up $0.18 or 7.20%.
The company noted that AditxtScore for COVID-19, which was first introduced in August of 2020, differentiates itself from traditional antibody tests by delivering a detailed view of an individual's immune response to multiple antigens associated with the SARS-CoV-2 virus.
"Everyone's immune response is unique to that individual. We have been studying individual immune responses to COVID-19 and COVID-19 vaccination," said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt.
AditxtScore for COVID-19 now includes virus-sSpecific infection blocking antibodies that assess the strength of an individual's immune response to SARS-CoV-2.
For comments and feedback: editorial@rttnews.com